Thanks for that postthe comment about valuation being PE 15x in...

Thanks for that post

the comment about valuation being PE 15x in 2023 and fact they will need to raise in next 6 months won't bode well for any short term money thoughts.

Question is how much will they raise and will they do it off the back of a dec quarter or stiff current holders further and do it early.  Would be good to see just where cost reductions are coming from and how they affect the ongoing sales and development  as you just can't stand still in this medical device  industry and need to really make $ as early as you can before something new takes the edge off your market.

Other companies must be interested at this sort of value and have all the sales , compliance staff internally already so could leverage off existing structure and reduce costs.   Is there a reason there is no control premium on offer apart from the aussie specs and biotechs getting poor valuations?

Watching to see exactly what direction these guys take and how their market matures / penetration goes to see if their guidance continues to be better.